FDA Expected To Allow Faster Approval of Some Generics

Law360, New York (October 14, 2003, 12:00 AM EDT) -- In a setback for large pharmaceutical companies, the U.S. Food and Drug Administration is expected to indicate Tuesday that it will allow makers of some generic drugs to use a little-known route to approval that could trim years off their time to reach the market, the Wall Street Journal reported.

The so-called 505(b)(2) process for generic drugs does not require the original proof of safety and effectiveness mandatory for approving new brand-name drugs, nor does it require the same reams of data needed for approving of...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.